NLS Pharmaceutics (NLSP) and Kadimastem, a clinical-stage cell therapy company specializing in the treatment of neurodegenerative diseases and potential cure for diabetes, announced that in a special general meeting of shareholders, Kadimastem’s shareholders approved the merger with NLS. NLS is also planning to convene a shareholder meeting for final approval of the merger.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- Biotech Alert: Searches spiking for these stocks today
- NLS Pharmaceutics Submits Research Abstracts to ASCP 2025
- NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence Treatment
- NLS Pharmaceutics and Kadimastem Move Toward Merger Approval
- Kadimastem calls for Special Meeting of Shareholders to approve NLS merger